Is Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock a Good Buy Or Sell After The Recent Correction?

August 12, 2021

Abeona Therapeutics Inc. (NASDAQ: ABEO) stock is down 13% in a month. However, the company recently reported encouraging ABO-102 test results in treating Sanfilippo Syndrome. Sanfilippo mainly affects the CNS causing neurological function deterioration. MRI data from Phase 1/2 Transfer A study showed that ABO-102 increased corpus callosum, amygdala, and grey matter volumes in three patients with Sanfilippo Syndrome Types A at 24 months relative to patients that didn’t receive…

Read More >>

Abeona Therapeutics Inc (NASDAQ: ABEO) Phase 1 / 2 Transpher A-Data Published

July 27, 2021

Abeona Therapeutics Inc (NASDAQ: ABEO) is an integrated player in gene therapy. It announced the MRI (Magnetic Resonance Imaging) data from its Phase 1 /2 Transhper A clinical study indicating an increase of grey matter in patients at 24 months compared to the patient without treatment. New data published: As per the company, MRI (Magnetic Resonance Imaging) data indicates ABO-102 led to an uptick in grey matter, amygdala volumes, and…

Read More >>